World Money Crisis Causes India’s Piramal To Delay Raising Funds
This article was originally published in PharmAsia News
India's Piramal Life Sciences says it has to put off launching a strategic stake sale as a way to raise funds, citing the global financial crisis. PLSL used to be the research and development arm of Piramal Healthcare until it was split off. Swati Piramal, director of the Piramal Group, said PLSL does not need immediate funds to continue operating, so it will defer its fund-raising plans until the world financial situation improves. (Click here for more
You may also be interested in...
MUMBAI - Abbott and Baxter are set to face strong competition in their traditional businesses of hospital anesthetic gas products as India's Piramal Healthcare has announced its acquisition of U.S. based Minrad International, a provider of generic inhalation anesthetics that include isoflurane, enflurane and sevoflurane. In addition, Minrad has filed an abbreviated new drug application for desflurane with U.S. FDA
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.